Skip Navigation

European Heart Journal 2002 23(3):194-197; doi:10.1053/euhj.2001.2911
Copyright © 2002 by the European Society of Cardiology.
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Gershlick, A. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gershlick, A. H.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Editorials

Acute coronary syndromes: optimizing the therapeutic options

A. H. Gershlick

Department Cardiology, University Hospitals of Leicester, U.K.

References

  1. N Engl J Med. 1994;330:956–961[Abstract/Free Full Text]
  2. Eur Heart J. 2000;21:1406–1433[Free Full Text]
  3. Heeschen C, Hamm CW, Goldman B. Troponin concentrations for stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofiban. Lancet. 1999;354:1757–1762[CrossRef][Web of Science][Medline]
  4. Lancet. 2001;357:1915–1924[CrossRef][Web of Science][Medline]
  5. Lancet. 1997;349:1429–1435[CrossRef][Web of Science][Medline]
  6. Topol EJ, Moliterno DJ, Herrmann HC. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, Tirofiban and abciximab, for the prevention of ischaemic events with percutaneous coronary revascularisation. N Engl J Med. 2001;344:1888–1894[Abstract/Free Full Text]
  7. Lancet. 1998;352:87–92[Web of Science][Medline]
  8. Lancet. 2000;356:2037–2044[CrossRef][Web of Science][Medline]
  9. Marzocchi A, Ortolani P, Piovaccari G. Coronary stenting for unstable angina: predictors of 30 day and long-term outcome. Cor Art Dis. 1999;10:81–88
  10. Collinson J, Flather MD, Fox KA. Clinical outcomes, risk stratification and practice patterns of unstable angina and myocardial infarction without St elevation: Prospective Registry of Acute Ischaemic Syndromes in the UK (PRAIS-UK). Eur Heart J. 2000;21:1450–1457[Abstract/Free Full Text]
  11. Ronner E, Boersma E, Akkerhuis KM. Patients with acute coronary syndromes without persistent ST elevation undergoing percutaneous coronary intervention benefit most from early intervention with protection by a glycoprotein IIb/IIIa receptor blocker. Eur Heart J. 2002;23:239–246[Abstract/Free Full Text]

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?



This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Gershlick, A. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gershlick, A. H.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?